
    
      In phase I of this study, a multi-center, randomized, placebo parallel control design was
      adopted. Enrolled subjects were randomly assigned to the experimental group or the placebo
      group.A total of 40 subjects are expected to be enrolled in about 4 centers.

      In phase II of this study, a multi-center, randomized, double-blind parallel,
      placebo-controlled design was adopted. Enrolled subjects were randomly assigned to the
      experimental group or the placebo group.About 120 subjects are expected to be enrolled in
      about 10 centers.
    
  